TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06345404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soquelitinib matching placebo tablets
Study: NCT05863221
Drug: ZYNRELEF 200Mg-6Mg Extended-Release Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYNRELEF® is an extended-release, fixed-ratio combination product that contains bupivacaine (a local anesthetic as the free base) and low-dose meloxicam (an NSAID) incorporated in a bioerodible polymer (termed Biochronomer®).
Study: NCT05463575
Drug: Ketohexokinase inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will be asked to take 300 mg of the KHKi in tablet form daily for 6 weeks in either period 1 or 2.
Study: NCT00292760
Drug: Methyprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06433726
Drug: BY101921 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral PARP7 Inhibitor
Study: NCT06332092
Drug: FID007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive FID007 via IV infusion at their assigned dose on Days 1, 8, and 15 of each 28-day cycle. Starting from Cycle 2, Cetuximab will be administered every 2 weeks on Days 1 and 15 of each 28-day cycle.
Study: NCT05626348
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate，10mg, po, quaque week (qw) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
Study: NCT06462495
Drug: [18F]F-PSMA-N5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.
Study: NCT05570539
Drug: BLU-5937 IR
Normalized name: Blu-Kote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive two single and multiple administrations of Immediate Release reference formulation
Study: NCT05570539
Drug: BLU-5937 ER
Normalized name: Blu-Kote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive single and multiple oral administrations of Extended Release formulation
Study: NCT04014712
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT06336993
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib (Ouyi Pharmaceutical Co., LTD., H20203296) was used twice a day for 3 weeks, 200mg/ time, to treat NSLBP;
Study: NCT05887726
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 mg/m2 i.v d1(21-day cycles)
Study: NCT05389813
Drug: Multivitamin with Minerals
Normalized name: multivitamin with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vit A 3000 IU, Vit B1 2.5mg, Vit B2 2.0mg, Vit B12 10mcg, Vit C 150mg, Vit D3 400 IU, Vit E10 IU, Biotin 25mcg, Nicotimamide 30mg, Calcium Pantothenate 3mg, Folic acid 800mcg, Iron Fumarate 18mg, Calcium 125mg, Magnesium Oxide 10mg, Iodine Potassium 150mcg, Manganese sulfate 0.5mg, Phosphorus 23.8mg, Copper sulfate 1.0mg, Molybdinium Sodium 0.10mg, Zinc Sulfate 5.0mg.
Study: NCT05779995
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation solution with matched volume
Study: NCT04806854
Drug: LUM-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT04922554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets resembling omadacycline orally, once daily (x 2 tablets)
Study: NCT05141474
Drug: Non-myeloablative Lymphodepletion (NMA-LD) Regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a NMA-LD chemotherapy based on Cyclophosphamide 60 mg/kg IV (once daily on Days -5 and -4) and Fludarabine 25 mg/m2 IV (once daily on Days -5 to -1).
Study: NCT06660394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered with matching placebo orally or through G-tube/ PEG tube
Study: NCT06038084
Drug: Bronpass Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day
Study: NCT06038084
Drug: Placebo of Erdos capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times a day (It is for the masking.)
Study: NCT06038084
Drug: Placebo of Bronpass Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day (It is for the masking.)
Study: NCT03946462
Drug: NO gas delivered during cardiac surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-operative NO gas at 20ppm blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system.
Study: NCT05907694
Drug: Optimal medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.
Study: NCT06660875
Drug: Serratus posterior superior intercostal plane block
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serratus posterior superior intercostal plane block is performed, under US guidance, before the surgical operation, and the induction of anesthesia, and when the patient is placed in the prone position.
Study: NCT06660875
Drug: Interscalene brachial plexus block and superficial cervical plexus block
Normalized name: Bos taurus solar plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: İnterscalene brachial plexus block and superficial cervical plexus block is performed, under US guidance, before the surgical operation, and the induction of anesthesia, and when the patient is placed in the prone position.
Study: NCT06433869
Drug: rmhTNF-NC
Normalized name: codeine phosphate / pseudoephedrine hydrochloride / triprolidine hydrochloride Oral Solution [Poly Hist NC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal injection of rmhTNF-NC is added to PD-1 inhibitor or bevacizumab.
Study: NCT06013163
Drug: Xenical® vs EMP 22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will first use Xenical® TID for 9 days and then EMP22TID for 9 days (in total 27 doses of each drug).
Study: NCT04712838
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A subjects were given oral F1 、F2 and F3 version SHR0302
Study: NCT04712838
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B subjects were given oral F1 、F3 and F2 version SHR0302
Study: NCT04712838
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C subjects were given oral F2 、F1 and F3 version SHR0302
Study: NCT04712838
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D subjects were given oral F2 、F3 and F1 version SHR0302
Study: NCT04712838
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group E subjects were given oral F3 、F1 and F2 version SHR0302
Study: NCT04712838
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group F subjects were given oral F3 、F2 and F1 version SHR0302
Study: NCT04794998
Drug: Recommended treatment schedule
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle Oxygen therapy
Study: NCT05908513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar chemical structure of NAC but without function
Study: NCT04980170
Drug: Clindamycin 300 mg
Normalized name: clindamycin 300 MG
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will be given clindamycin 300 mg twice daily for 5 days after dental implant
Study: NCT02386007
Drug: DW-3101_150mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02386007
Drug: DW-3101_300mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02386007
Drug: DW-3101_600mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02386007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05665387
Drug: 0.1% STN1013600 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% STN1013600 ophthalmic solution 1 drop BID for 2 months
Study: NCT05665387
Drug: 0.3% STN1013600 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% STN1013600 ophthalmic solution 1 drop BID for 2 months
Study: NCT05665387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ophthalmic solution 1 drop BID for 2 months
Study: NCT04995354
Drug: Hydrogel
Normalized name: HYDROGEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-medicated self-healing hydrogel to be applied three times a day for 1 week
Study: NCT05836233
Drug: Pulmonary Vasodilators
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right heart catheterization via Swan Ganz catether will be performed under optimal medical therapy within 90 days before LVAD implantation. We will record the timing between RHC and LVAD implantation.~Vasodilator challenge will be performed through intravenous nitroprusside administration and titration (by 5 minutes intervals) until symptoms (flushing or hypotension) onset or systolic systemic pressure drop below 85 mmHg (target dose).~Dobutamine or phosphodiesterase inhibitors infusion could be performed at clinician's discretion.~All haemodynamic measurements will be repeated after nitroprusside infusion and titration until the target dose.
Study: NCT04983264
Drug: GBT021601
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets and capsules which contain GBT021601 drug substance
Study: NCT05519410
Drug: HAIC-FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
Study: NCT05212116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Matching Placebo for SDI-118 is mannitol in capsules.
Study: NCT06461442
Drug: 5Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will apply 5% 5-Fluorouracil cream in a thin layer twice daily for 4 weeks on the treatment areas randomized to this treatment.
Study: NCT05755854
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous cyclophosphamide on days -5、-4、and -3, the infusion dose is adjusted according to the subject's condition
Study: NCT05755854
Drug: Zoredronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoredronic acid 50ug/kg 24 hours before cell infusion（or according to the dosage of the instruction）（If applicable）
Study: NCT05657834
Drug: [14C]-TVB-2640
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of TVB-2640 oral administration
Study: NCT04794998
Drug: Control treatment schedule
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimens different from the recommended one according to family phisicians personal practice.
Study: NCT05104125
Drug: ASC40 25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg of ASC40 orally once daily for 12 weeks.
Study: NCT05685550
Drug: Toposide capsules combined with anrotinib and Emvolizumab group
Normalized name: picodralazine and diuretics, combinations with psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elderly patients with extensive SCLC were given etoposide capsules 100mg PO qd\*7d and Envollizumab 300mg/ time IH Q3W in combination with anrotinib 12mg PO qd\*14d,every 21 days until disease progression or adverse reactions that were tolerated.
Study: NCT06520683
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Adjuvant therapy is not mandatory.~* Optional adjuvant regimens include FOLFOX, CapeOX, 5-FU+LV, or Capecitabine.
Study: NCT03822858
Drug: Intrathecal MSC-NP injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Between 5 to 10 million MSC-NPs will be administered intrathecally in each dose.~10 million cells is the maximum dose. Treatment will consist of 3-5 doses spaced 3 months apart.
Study: NCT06310746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is planned to enroll 8-10 subjects in each of seven dose groups (0.25 mg/kg, 1.0 mg/kg, 4.0 mg/kg, 12 mg/kg, 25 mg/kg, 50 mg/kg, and 70 mg/kg).
Study: NCT05104125
Drug: ASC40 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg of ASC40 orally once daily for 12 weeks.
Study: NCT05104125
Drug: ASC40 75mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mg of ASC40 orally once daily for 12 weeks.
Study: NCT05104125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally once daily for 12 weeks.
Study: NCT04112199
Drug: BIV201 continuous infusion
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIV201 continuous infusion with terlipressin for a total of two 28 day cycles. Initiate treatment at 3 mg per 24 hour period and titrate stepwise up to a maximum of 8 mg per 24 hour period based on tolerability and response.
Study: NCT06391450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04964375
Drug: ABSK043 oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABSK043 is a novel, oral small molecule inhibitor of PD-L1
Study: NCT06358963
Drug: Non-Medicare Drugs
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: and Group C did not receive any medication; after the two-month study period, the clinical periodontal parameters were reassessed. Additionally, to compare teh total antioxidant capacity in saliva before and after teh intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at teh beginning and end of teh study for analysis using UV-spectrophotometric methods, furthermore, teh following criteria determined teh selection of eligible participants for dis study.
Study: NCT05884970
Drug: 100 mcg Salbutamol Ventolin GSK and 300 mcg Salbutamol Ventolin GSK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efficacy of Salbutamol Sandoz will be compared to Salbutamol Ventolin GSK (reference)
Study: NCT04876924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BBP-711
Study: NCT05104229
Drug: Aspirin 81Mg Ec Tab
Normalized name: ASPIRIN 81MG EC TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 81Mg Ec Tab by mouth twice daily starting the day after surgery until hospital discharge, then for 30 days
Study: NCT05104229
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care VTE prophylaxis
Study: NCT05863832
Drug: Ciprodiazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofolxacin 500 mg / Metronidazole 500 mg
Study: NCT05281471
Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered according to local practice
Study: NCT04831086
Drug: Steroid Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids doses will be optimized in the intervention group according the risk based on predictive models
Study: NCT05434091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
Study: NCT05717374
Drug: caudal block using methylprednisolone
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive 0.5 ml/kg volume (bupivacaine 0.25% + methylprednisolone 0.5mg/kg) through the sacral hiatus
Study: NCT04080895
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
Study: NCT05428150
Drug: Esbriet 267 MG Oral Capsule
Normalized name: Esbriet 267 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference Formulation
Study: NCT05959486
Drug: BR6002A
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT05959486
Drug: BR6002B
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT05959486
Drug: BR6002
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule administered alone
Study: NCT05740748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo sc q4wks for 20 weeks
Study: NCT05524155
Drug: HAIC
Normalized name: Hepatic Arterial Infusion Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
Study: NCT05292040
Drug: LY3857210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05650216
Drug: Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Neoadjuvant treatment period:~   Radiotherapy: Primary lesions and adjacent lymph nodes: The mode of involved field irradiation (IFI) is adopted, no preventive radiation is given. The total dose is 41.4Gy, 1.8Gy/23f. Distal lymph nodes ≥ 5cm away from the primary lesion: low-dose radiotherapy with a total dose of 4Gy, 0.5Gy/8f, Day1 to Day4, Day22 to Day25.~   Chemotherapy: Carboplatin(AUC=2), Nab-paclitaxel(80mg/m2), Day1/8/15/22/29. Immunotherapy: Camrelizumab(200mg, Day5, Day26).~2. Perioperative period:~   Undergo surgery within 4-6 weeks after neoadjuvant therapy~3. Adjuvant treatment period:~Camrelizumab: (200mg, Q3W)，continued for up to 1 years，until PD or intolerable toxicity.
Study: NCT05953506
Drug: HS-10506 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered orally once on Day 1.
Study: NCT06459869
Drug: Capecitabine oral administration
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy
Study: NCT06207253
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
Study: NCT06207253
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: placement of intracanal medication for the three groups will be done after cleaning and shaping of the root canals and it will be left for one week.
Study: NCT06408532
Drug: IDegLira
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants in this group will be switched to IDegLira once daily injection therapy.
Study: NCT05057572
Drug: Standard Medical Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Arm B will receive standard medical therapy.SMT (as described) that is Grade II ascites - Lasilactone (20/50) OD then Change after 1 week as per response, monitor diuretic intolerance.~* Grade III ascites will undergo large volume paracentesis, lasilactone (20/50) OD Both groups will receive albumin as indicated (LT references as per protocol will be send for eligible patients)
Study: NCT06449703
Drug: Xultophy®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xultophy®
Study: NCT04183595
Drug: (N1, N3-bis(2- mercaptoethyl)isophthalamide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg / day NBMI treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours, at the start of treatment, the principal investigator or his delegate will verify the intake of the first dose and deliver a blister pack corresponding to the remaining NBMI capsules, at visit day 14 research subjects will be asked to return the packaging with the remaining capsules or not, in order to estimate adherence to treatment.
Study: NCT05154695
Drug: B.prolotherapy group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B receives hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
Study: NCT06084130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: corn-starch contained in identical white-color opaque medicine capsule
Study: NCT05642910
Drug: Paxlovid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received Paxlovid orally for 5 consecutive days (10 doses in total).
Study: NCT05193734
Drug: Pertagen®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule:~Group Pertagen will receive two doses of Pertagen®. (one vaccination on Day 0 and 6 months later for each volunteer.)~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle.
Study: NCT05193734
Drug: Revaxis®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule:~Group Control will receive one dose of Revaxis® on Day 0 followed by 1 dose of Pertagen® 6 months later for each volunteer.~Mode of Administration:~Intramuscular injection into the deltoid region of the upper extremity, using a syringe with a 1 to 1.5 inch #25-gauge sterile needle.
Study: NCT04842435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In a Stage 1 study, Placebo is administered to clinical study subjects randomized to groups 4 by intravenous drip at a dose of 1 mL/kg.~The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, placebo is administered to clinical study subjects randomized to group 2 by intravenous drip at a dose equal to the study drug dose.
Study: NCT06603766
Drug: IV Magnesium Sulfate
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO₄'s mechanism in PPHN includes activating cellular processes, modulating membrane excitability, and acting as a physiological calcium antagonist. It exerts sedative, muscle relaxant, and bronchodilatory properties, while concurrently inducing a state of alkalosis.
Study: NCT06603766
Drug: Inhalational magnesium sulfate
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: It gives us the same mechanism of action as IV MgSO4 with less side effects.
Study: NCT01504282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: balanced salt solution (BSS)